Genetic Diagnosis of Epileptic Encephalopathies

Epileptic encephalopathies constitute a spectrum of severe, early-onset seizure disorders in which persistent epileptic activity itself contributes to cognitive, motor and behavioural impairment. Genetic aetiologies account for a significant proportion of these syndromes, reflecting remarkable heterogeneity across ion channels, synaptic proteins, transcription factors and regulators of neuronal metabolism. Advances in sequencing technologies—from targeted gene panels to whole-exome and whole-genome sequencing—have transformed diagnostic pathways by enabling rapid identification of pathogenic variants, guiding precision therapeutics and informing prognosis and genetic counselling. Emerging approaches such as DNA methylation profiling and long-read sequencing further expand diagnostic yield, particularly in cases unexplained by standard variant calling. Early genetic diagnosis not only accelerates appropriate therapy selection—including off-label use of channel modulators and dietary interventions—but also reduces unnecessary investigations and alleviates familial uncertainty. Ongoing challenges remain in variant interpretation, detection of mosaicism, structural rearrangements and non-coding variants. Integration of multidisciplinary clinical, genetic and epigenetic data holds promise for improved diagnostic precision and development of targeted treatments, underscoring the global imperative of genomics in paediatric neurology.

Research from Nature Portfolio

Recent studies have demonstrated the diagnostic utility of genome-wide DNA methylation array analysis in individuals with genetically unsolved developmental and epileptic encephalopathies. By interrogating peripheral blood samples, researchers identified rare differentially methylated regions and distinct episignatures, uncovering balanced translocations, CG-rich repeat expansions and copy number variants underlying previously undetected cases. Refinement of the CHD2 episignature has provided novel insights into its pathophysiology and increased the diagnostic yield by revealing causative and candidate variants in a subset of unresolved patients. This epigenetic approach complements sequence-based testing and underscores the value of integrating methylation profiling into standard diagnostic workflows.

Genetic Diagnosis of Epileptic Encephalopathies publication trend

The graph below shows the total number of articles in genetic diagnosis of epileptic encephalopathies across all publications each year (not limited to Nature Index journals).

Technical terms

Epileptic encephalopathy: A group of severe epilepsy syndromes in which ongoing seizures exacerbate developmental impairment.

Developmental and epileptic encephalopathies (DEEs): Disorders characterised by early-onset seizures accompanied by developmental regression due to genetic causes.

Exome sequencing: A technique to sequence all protein-coding regions of the genome.

Genome sequencing: Comprehensive analysis of an individual’s entire DNA sequence, encompassing both coding and non-coding regions.

Targeted gene panel: A selected set of genes known to be associated with a specific disorder, sequenced simultaneously for diagnostic purposes.

DNA methylation episignature: A disease-specific pattern of methyl groups on DNA that aids in diagnosis when sequence variants are absent.

Differentially methylated region (DMR): A genomic segment showing altered methylation linked to disease pathology.

De novo variant: A genetic alteration arising for the first time in an individual, not inherited from either parent.

References

1. Diagnostic utility of DNA methylation analysis in genetically unsolved pediatric epilepsies and CHD2 episignature refinement. Nature Communications (2024).
2. Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study. The Lancet Neurology (2023).
3. Genes4Epilepsy: An epilepsy gene resource. Epilepsia (2023).
4. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. Molecular Genetics & Genomic Medicine (2018).